logo

OncoTrials - мониторинг клинических исследований

Новые исследования (2025-02-13):

NCT06821880 (Множественная миелома)
NCT06821880 (Хронический лимфолейкоз | Лимфома из малых лимфоцитов)
NCT06822829 (Диффузная крупноклеточная В-клеточная лимфома)
NCT06823960 (Лимфома маргинальной зоны)


Найдено исследований: 11

NCT06823960 (добавлено:  Сегодня! )

Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Теги:  #Relapsed|Refractory 

Локации: AO di Cosenza, P.O. "Annunziata" - UOC di Ematologia; Cosenza; Italy,AOU Città della Salute e della Scienza, "Le Molinette" - Divisione di Ematologia; Torino; Italy,AOU di Ferrara_ UO di Ematologia - Dipartimento di Oncologia e Medicine Specialistiche; Ferrara; Italy,AOU SS Antonio e Biagio e Cesare Arrigo; Alessandria; Italy,ASST Grande Ospedale Metropolitano Niguarda _ UOC Ematologia; Milano; Italy,Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale Maggiore- SC (UCO) Ematologia; Trieste; Italy,Fondazione PTV Policlinico Tor Vergata- U.O.C. Patologie Linfoproliferative; Roma; Italy,IOV - Istituto Oncologico Veneto - IRCCS _UOC Oncologia1; Padova; Italy,IRCCS-AOU di Bologna; Bologna; Italy,Istituto Clinico Humanitas IRCCS - UO Ematologia; Milano; Italy,Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS; Meldola; Forlì Cesena; Italy,Ospedale Ca` Foncello, Azienda ULSS n. 2 Marca trevigiana - UOC Ematologia Dipartimento di Medicina; Treviso; Italy,Ospedale Santa Maria d

NCT06806488 (добавлено: 2025-02-05)

Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Retrospective Observational Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Локации: IRCCS Azienda Ospedaliero - Universitaria di Bologna; Bologna; Italy

NCT06390956 (добавлено: 2025-02-04)

Pirtobrutinib in Combination With Rituximab in Newly Diagnosed Marginal Zone Lymphoma (R+Pirto in Newly Diagnosed MZL)

A Phase II Study of Pirtobrutinib in Combination With Rituximab in Newly Diagnosed Marginal Zone Lymphoma: A Risk Adapted Approach

Теги:  #Relapsed|Refractory 

Локации: Huntsman Cancer Institute at University of Utah; Salt Lake City; Utah; United States

NCT06569680 (добавлено: 2024-11-26)

Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

Phase II Trial of Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma (EMZL) (ML44933)

Теги:  #Relapsed|Refractory 

Локации: University of Miami; Miami; Florida; United States

NCT06667687 (добавлено: 2024-11-03)

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin`s Lymphoma

A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-291 in Non-Hodgkin`s Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Carolina BioOncology Institute /ID# 265259; Huntersville; North Carolina; United States,Hadassah Medical Center-Hebrew University /ID# 261658; Jerusalem; Yerushalayim; Israel,START Mountain Region /ID# 267592; West Valley City; Utah; United States,Tel Aviv Sourasky Medical Center /ID# 261659; Tel Aviv; Tel-Aviv; Israel,The Cancer Institute Hospital Of JFCR /ID# 267470; Koto-ku; Tokyo; Japan,Virginia Cancer Specialists - Fairfax /ID# 265082; Fairfax; Virginia; United States

NCT06647732 (добавлено: 2024-10-19)

Zanubrutinib Plus Rituximab As Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

Zanubrutinib Plus Rituximab As Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT): a Single-arm, Open-label, Multicenter, Phase II Study(ZAMA)

Теги:  #Relapsed|Refractory 

Локации: Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University; Guangzhou; Guangdong; China

NCT06442475 (добавлено: 2024-10-15)

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma

Локации: Fred Hutch/University of Washington Cancer Consortium; Seattle; Washington; United States

NCT06544265 (добавлено: 2024-10-15)

SynKIR-310 for Relapsed/Refractory B-NHL

A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced with CD19 KIR-CAR, in Participants with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute; Denver; Colorado; United States

NCT06566807 (добавлено: 2024-10-15)

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma: A Phase 2, Single-Arm, Prospective, Multicenter Clinical Study

Теги:  #Newly diagnosed 

Локации: The Affiliated Huaian No.1 People`s Hospital of Nanjing Medical University#Huai`an First People`s Hospital#; Huai`an,; Jiangsu; China

NCT06583837 (добавлено: 2024-10-15)

Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma

A Prospective, Multicenter, Phase II Study of Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of Local-stage Mucosa Associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

Теги:  #Newly diagnosed 

Локации: Fudan University Shanghai Cancer Center; Shanghai; Shanghai; China

NCT06592170 (добавлено: 2024-10-15)

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

A Single Arm, Open Center, Multicenter Clinical Study of Frontline Treatment of Marginal Zone Lymphoma Patients (MZL) With Linperlisib Combined With Obinutuzumab

Теги:  #Newly diagnosed 

Локации: The First Hospital of Jilin University; Changchun; Jilin; China